4-2018

Antibiotic Resistance Rates for *Pseudomonas aeruginosa* Clinical Respiratory and Bloodstream Isolates Among the Veterans Affairs Healthcare System from 2009 to 2013

Haley J. Appaneal
University of Rhode Island

R. Caffrey
University of Rhode Island, aisling_caffrey@uri.edu

Lan Jiang

David Dosa

Leonard A. Mermel
University of Rhode Island
Follow this and additional works at: https://digitalcommons.uri.edu/php_facpubs

The University of Rhode Island Faculty have made this article openly available.
Please let us know how Open Access to this research benefits you.

This is a pre-publication author manuscript of the final, published article.

Terms of Use

This article is made available under the terms and conditions applicable towards Open Access Policy Articles, as set forth in our [Terms of Use](#).

Citation/Publisher Attribution

Appaneal HJ, Caffrey AR, Jiang L, Dosa D, Mermel LA, LaPlante KL. Diagn Microbiol Infect Dis. 2018 Apr;90(4):311-315. doi: 10.1016/j.diagmicrobio.2017.11.022
Available at: <https://doi.org/10.1016/j.diagmicrobio.2017.11.022>

This Article is brought to you for free and open access by the Pharmacy Practice at DigitalCommons@URI. It has been accepted for inclusion in Pharmacy Practice Faculty Publications by an authorized administrator of DigitalCommons@URI. For more information, please contact digitalcommons-group@uri.edu.

Authors

Haley J. Appaneal, R. Caffrey, Lan Jiang, David Dosa, Leonard A. Mermel, and Kerry L. LaPlante

**Antibiotic Resistance Rates for *Pseudomonas aeruginosa* Clinical Respiratory and
Bloodstream Isolates Among the Veterans Affairs Healthcare System from 2009 to 2013**

Haley J. Appaneal^{1,2,3*}, Aisling R. Caffrey^{1,2,3,4}, Lan Jiang³, David Dosa^{3,5}, Leonard A. Mermel^{2,6,7},
and Kerry L. LaPlante^{1,2,3,7}

1. Veterans Affairs Medical Center, Rhode Island Infectious Diseases Research Program,
Providence, RI

2. University of Rhode Island, Department of Pharmacy Practice, College of Pharmacy,
Kingston, RI

3. Veterans Affairs Medical Center, Center of Innovation in Long Term Services and Supports,
Providence, RI

4. Brown University School of Public Health, Providence, RI

5. Center for Gerontology and HealthCare Research, Brown University School of Public Health,
Providence, RI, United States

6. Department of Epidemiology and Infection Control, Rhode Island Hospital, Providence, RI,
United States

7. Warren Alpert Medical School of Brown University, Division of Infectious Diseases,
Providence, RI

Running title: *Pseudomonas aeruginosa* Resistance

Abstract word count: 150

Body of the text word count: 1,665

Keywords: *Pseudomonas aeruginosa*, resistance, multidrug-resistance

*Corresponding Author

Haley J. Appaneal, Pharm.D., Research Health Science Specialist, Providence Veterans Affairs
Medical Center, 830 Chalkstone Ave, Providence, RI 02908, 401-273-7100 ext 4150 (office);
haley.morrill@va.gov

Abstract

Pseudomonas aeruginosa is a major cause of healthcare-associated infections and resistance among isolates is an increasing burden. The study purpose was to describe national resistance rates for clinical *P. aeruginosa* respiratory and bloodstream cultures and the prevalence of multidrug-resistant (MDR) *P. aeruginosa* within the Veterans Affairs (VA). MDR was defined as non-susceptibility to at least one drug in at least 3 of the following 5 categories: carbapenems, extended-spectrum cephalosporins, aminoglycosides, and piperacillin/tazobactam. We reviewed 24,562 *P. aeruginosa* respiratory and bloodstream isolates across 126 VA facilities between 2009 to 2013. Most isolates were collected from inpatient settings (82%). Resistance was highest in fluoroquinolones (33%) and exceeded 20% for all classes assessed (carbapenems, extended-spectrum cephalosporins, aminoglycosides, and piperacillin/tazobactam). Resistance was higher in inpatient settings and in respiratory isolates. Prevalence of MDR was 20% overall (22% for inpatient isolates, 11% outpatient, 21% respiratory, 17% bloodstream). Our findings are consistent with previous surveillance reports

.

Body of the Text

Introduction

Pseudomonas aeruginosa is a major cause of healthcare-associated infections.(1) *P. aeruginosa* is a leading cause of severe Gram-negative infections, including pneumonia and bloodstream infections, which are associated with high mortality rates.(2, 3) Antimicrobial resistance and multidrug-resistance (MDR) among *P. aeruginosa* isolates collected from hospitalized patients are increasing and threaten the appropriate treatment of patients with severe infections.(4, 5) *P. aeruginosa* is also an important cause of community-acquired pneumonia in patients with underlying lung disease, alcoholism and compromised immune function.(6-8) However, surveillance of isolates from the community is less frequent than from healthcare settings and nationwide resistance rates in community setting are less well understood.

The Veterans Affairs (VA) is the largest integrated healthcare system in the United States (US), providing care to approximately 9 million Veterans in 140 medical centers and 1200 outpatient clinics. Clinical antimicrobial susceptibility data from VA electronic datasets support a nationwide description of *P. aeruginosa* resistance.(9) The aim of this study was to assess national antibiotic resistance rates for clinical *P. aeruginosa* respiratory and bloodstream cultures, as well as determine the prevalence of MDR *P. aeruginosa* in the VA system.

Methods

We evaluated antimicrobial susceptibility from all VA hospitals, long-term care units and outpatient facilities in the United States.(9) We included all *P. aeruginosa* blood and respiratory clinical cultures collected between January 1, 2009 to December 31, 2013 from patients aged 18 years or older.

We defined antibiotic resistance per the CDC Antibiotic Resistance Patient Safety Atlas Phenotype Definitions.(10) We included the first isolate per person, per facility, per month.(10) Antibiotic susceptibility was based on the reported microbiology results of the clinical culture. As microbiology practices and susceptibility breakpoints are not standardized throughout the VA system, we applied the 2014 Clinical Laboratory Standards Institute (CLSI) breakpoints to determine non-susceptibility where numeric minimum inhibitory concentrations (MIC) data were available.(11) Where MIC values were not available, we used the reported textual interpretation (i.e., resistant [R], intermediate [I], or susceptible [S]).(12) In cases of duplicate (same patient, same isolate, same day), yet conflicting antimicrobial susceptibility results, we included the most resistant result (i.e., R > I > S).(12)

We grouped individual antibiotic agents into five categories as follows: extended-spectrum cephalosporins (ceftazidime and cefepime); fluoroquinolones (levofloxacin and ciprofloxacin); aminoglycosides (amikacin, gentamicin, and tobramycin); carbapenems (imipenem, meropenem, and doripenem), and piperacillin/tazobactam (piperacillin and piperacillin/tazobactam).(10) Resistance was defined as an isolate that was not susceptible, thus either intermediate or resistant, to at least one drug in that category.(10) Multidrug-resistance (MDR) was defined as non-susceptibility to at least one drug in at least 3 of the 5 categories (extended-spectrum cephalosporins, aminoglycosides, carbapenems, and piperacillin/tazobactam).(10)

We presented summary rates of antibiotic resistance for each of the five antibiotic categories assessed and prevalence of MDR among *P. aeruginosa* isolates. Antibiotic resistance for each antibiotic category was calculated as the number of non-susceptible isolates divided by the total number of isolates tested. Prevalence of MDR was calculated as the number of MDR isolates divided by the total number of isolates tested. We presented overall rates of antibiotic resistance

and MDR over the entire study period, and presented rates by treatment setting, source, and CDC region. All analyses will be performed with SAS (SAS, Cary, NC, Version 9.2).

Results

We identified 24,562 *P. aeruginosa* isolates from 126 VA facilities over the 5-year study period; 82% were from inpatient settings. Most isolates were obtained from white (72%), male (97%), Veterans 65 years and older (59%). Resistance was highest for fluoroquinolones (33%) and lowest for the piperacillin class (piperacillin/tazobactam and piperacillin, 21%; Table 1). Resistance to carbapenems, extended-spectrum cephalosporins, and aminoglycosides was 24-25%. Resistance was higher in inpatient settings (Table 1) and in respiratory isolates (Table 2). Prevalence of MDR was 20% overall (22% and 11% for inpatient and outpatient settings, respectively; and 21% and 17% for respiratory and bloodstream isolates, respectively).

Among inpatient cultures, resistance rates were highest in the Pacific region (fluoroquinolones 42%, carbapenems 35%, MDR 30%) and lowest in the Mountain (fluoroquinolones 27%, carbapenems 17%, MDR 14%) and New England regions (fluoroquinolones 27%, piperacillin class 17%, MDR 16%) (Figure 1). Outpatient resistance rates were highest in the Mid-Atlantic region (fluoroquinolones 31%, carbapenems 22%, MDR 21%) and lowest in the New England (fluoroquinolones 20%, carbapenems 10%, MDR 6%) and West South Central regions (fluoroquinolones 17%, carbapenems 11%, MDR 7%) (Figure 2).

Discussion

Treatment of *P. aeruginosa* infections are challenging due to intrinsic resistance and ability to develop resistance to multiple antimicrobial classes.(13, 14) These features limit treatment options and complicate selection of appropriate initial antibiotic treatment, which can have devastating consequences on patient outcomes.(14, 15) We observed rates of resistance in

1 excess of 20% for all antimicrobial classes assessed. Our findings are similar to previous
2 surveillance reports, and in some cases, resistance was higher in our study.(4, 5, 13) The most
3 recent study of 7,452 *P. aeruginosa* isolates from 79 US medical centers between 2012 to 2014
4 demonstrated non-susceptibility of 20% for piperacillin-tazobactam, 18% for meropenem, and
5 16% for ceftazidime, compared to our findings of 24% resistance for piperacillin-tazobactam and
6 piperacillin, 27% for carbapenem, and 27% for extended-spectrum cephalosporins.(13)

7
8 Prior surveillance data suggests a trend towards stabilized or decreased antimicrobial resistance
9 to several agents among *P. aeruginosa* isolates in the US.(13, 16) Recent data from the VA
10 system has demonstrated this trend in decreased antimicrobial resistance among *P. aeruginosa*
11 isolates.(17) We observed similar resistance rates among bloodstream isolates to those
12 previously reported. We also found higher resistance rates among nosocomial isolates and
13 variations in resistance rates by CDC region.(17)

14
15 Overall, we demonstrated high rates of MDR among *P. aeruginosa* isolates (20%), with higher
16 rates in the inpatient vs. outpatient setting (22% vs. 11% outpatient) and pulmonary vs. blood
17 source (21% vs. 17% blood). National surveillance data from 2000 to 2009, including 205,526 *P.*
18 *aeruginosa* isolates from pneumonia and bloodstream infections, demonstrated prevalence rates
19 of MDR among *P. aeruginosa* isolates similar to our findings (22% for pneumonia; 15% for
20 bloodstream infections).(4) Among bloodstream isolates in a recent VA study, there was a lower
21 rate of MDR than we had observed.(17) Differences in methods used to define MDR likely explain
22 variations in reported MDR rates. While we used the CDC Patient Atlas MDR definitions requiring
23 non-susceptibility to at least one antibiotic in at least 3 different classes, the previous study
24 required resistance to all antibiotics tested in at least 3 different classes.(17)

25
26 Finally, our results from the outpatient setting are noteworthy. None of the antimicrobial classes

1 assessed provided greater than 10% anti-pseudomonal coverage and rates of MDR were 11%
2 nationally (Table 1), exceeding 20% in the Mid Atlantic region (Figure 2). Inappropriate initial
3 empiric antimicrobial treatment is thus an important concern in the treatment of community-onset
4 *P. aeruginosa* infections. Inappropriate initial empiric antimicrobial treatment is common
5 inpatients with community-acquired *P. aeruginosa* bloodstream infections and those with
6 pneumonia and it is associated with greater mortality.(18, 19) While combination therapy remains
7 controversial, it may be important approach to minimize inappropriate initial therapy, especially in
8 regions with the highest resistance rates.

9
10 Our findings add to previous work, highlighting antibiotic resistance among *P. aeruginosa* isolates
11 nationally. We demonstrated that resistance to five key and commonly used antimicrobial classes
12 was high despite treatment setting, culture source, and region. Due to the poor outcomes
13 associated with inappropriate treatment of severe *P. aeruginosa* isolates, facilities should
14 consider developing treatment pathways or policies, which potentially include use of combination
15 therapy and/or newer antimicrobial options, for infections in which MDR organisms are suspected.
16 Additionally, knowledge of specific risk factors for resistant and MDR *P. aeruginosa* isolates would
17 be important to help clinicians better care for patients with infections due to resistant pathogens,
18 and is an important next step to this work. Finally, antimicrobial stewardship programs are
19 mandated in the acute care setting in the VA, however increased efforts in the outpatient setting
20 are warranted and urgently needed.(20) Increased assistance with antibiotic selection could help
21 to manage these difficult to treat infections due resistant *P. aeruginosa* isolates and potentially
22 improve patient outcomes.

23
24 There are limitations to this observational, cross-sectional work. The inclusion of all positive *P.*
25 *aeruginosa* respiratory and blood cultures enabled us to describe ecological resistance in the VA
26 system, however, we did not distinguish between colonization from true infection. Additionally,

1 there is the potential for misclassification of community-acquired isolates, as we did not assess
2 healthcare contact prior to outpatient culture date. Another limitation is that our definition of
3 resistance was based on non-susceptibility. Therefore, isolates that were intermediate met our
4 definition of resistance, and as such we may have overestimated true resistance. However, our
5 definitions are consistent with those used by the CDC Patient Safety Atlas.(10) There is
6 heterogeneity among microbiology laboratories in the VA system and different testing methods
7 among labs may have impacted our findings. We applied CLSI susceptibility breakpoints where
8 MIC data was available, however MIC data was not available for all isolates. In such cases we
9 had to rely on the interpretation as provided by the testing microbiology laboratory. Finally, the
10 generalizability of the study population and results are limited to the VA, a fully integrated
11 healthcare system consisting of largely older, white male patients.

12
13 In summary, among nearly 25,000 clinical *P. aeruginosa* respiratory and bloodstream isolates,
14 resistance to five key and commonly used antimicrobial classes (fluoroquinolones, carbapenems,
15 extended-spectrum cephalosporins, aminoglycosides, and piperacillin group) exceeded 20% and
16 20% of isolates were MDR. Resistance was higher among isolates collected from the inpatient
17 versus outpatient setting and from a respiratory source.

1 **Acknowledgements.**

2 The views expressed are those of the authors and do not necessarily reflect the position or policy
3 of the United States Department of Veterans Affairs. This material is based upon work supported,
4 in part, by the Office of Research and Development, Department of Veterans Affairs.

5
6 *Conflict of interest.*

7 Haley J. Morrill is supported in part by a Career Development Award, Department of Veterans
8 Affairs, and has received research funding from Merck (Cubist).

9 Aisling R. Caffrey has received research funding from Pfizer Inc and Merck (Cubist), and The
10 Medicines Company.

11 Lan Jiang has no conflicts.

12 David Dosa is a Veteran's Affairs government employee. He has received research funding
13 through the VA, The West Foundation, and National Institutes of Aging.

14 Leonard A. Mermel has served as a consultant for The Medicines Company and has received
15 research support from BARD.

16 Kerry L. LaPlante has received research funding, or acted as an advisor or consultant for
17 BARD/Davol, Merck (Cubist), Ocean Spray, Allergan, Pfizer Inc, and The Medicines Company.

References

1. **Gaynes R, Edwards JR, National Nosocomial Infections Surveillance S.** 2005. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis **41**:848-854.
2. **Hattemer A, Hauser A, Diaz M, Scheetz M, Shah N, Allen JP, Porhomayon J, El-Solh AA.** 2013. Bacterial and clinical characteristics of health care- and community-acquired bloodstream infections due to *Pseudomonas aeruginosa*. Antimicrob Agents Chemother **57**:3969-3975.
3. **Rodrigo-Troyano A, Sibila O.** 2017. The respiratory threat posed by multidrug resistant Gram-negative bacteria. Respirology doi:10.1111/resp.13115.
4. **Zilberberg MD, Shorr AF.** 2013. Prevalence of multidrug-resistant *Pseudomonas aeruginosa* and carbapenem-resistant Enterobacteriaceae among specimens from hospitalized patients with pneumonia and bloodstream infections in the United States from 2000 to 2009. J Hosp Med **8**:559-563.
5. **Sader HS, Farrell DJ, Flamm RK, Jones RN.** 2014. Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009-2012. Int J Antimicrob Agents **43**:328-334.
6. **Restrepo MI, Mortensen EM, Velez JA, Frei C, Anzueto A.** 2008. A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU. Chest **133**:610-617.
7. **Arancibia F, Bauer TT, Ewig S, Mensa J, Gonzalez J, Niederman MS, Torres A.** 2002. Community-acquired pneumonia due to gram-negative bacteria and *pseudomonas aeruginosa*: incidence, risk, and prognosis. Arch Intern Med **162**:1849-1858.
8. **Prina E, Ranzani OT, Polverino E, Cilloniz C, Ferrer M, Fernandez L, Puig de la Bellacasa J, Menendez R, Mensa J, Torres A.** 2015. Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia. Ann Am Thorac Soc **12**:153-160.
9. **Department of Veterans Affairs.** Department of Veterans Affairs Statistics at a Glance. http://www.va.gov/vetdata/docs/Quickfacts/Stats_at_a_glance_08_27_15.pdf Last updated: 06/30/2015. Accessed: 03/17/2016.
10. **Centers for Disease Control and Prevention.** Antibiotic Resistance Patient Safety Atlas. Phenotype Definitions. Accessed April 13, 2016. Available at "<http://gis.cdc.gov/grasp/PSA/Downloads/ARPatientSafetyAtlas-PhenotypeDefinitions.pdf>".
11. **Clinical Laboratory Standards Institute (CLSI).** January 2015. CLSI document M100-S25, . Performace Standards for Antimicrobial Susceptibility Testing; Twenty-Fifth Informational Supplement.

12. **Centers for Disease Control and Prevention (CDC). National Healthcare Safety Network (NHSN).** January 2014. Available at: <http://www.cdc.gov/nhsn/PDFs/pscManual/11pscAURcurrent.pdf> (accessed November 2014). Antimicrobial Use and Resistance (AUR) Module.
13. **Sader HS, Huband MD, Castanheira M, Flamm RK.** 2017. *Pseudomonas aeruginosa* Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States. *Antimicrob Agents Chemother* **61**.
14. **Lister PD, Wolter DJ, Hanson ND.** 2009. Antibacterial-resistant *Pseudomonas aeruginosa*: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. *Clin Microbiol Rev* **22**:582-610.
15. **Micek ST, Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH.** 2005. *Pseudomonas aeruginosa* bloodstream infection: importance of appropriate initial antimicrobial treatment. *Antimicrob Agents Chemother* **49**:1306-1311.
16. **Weiner LM, Webb AK, Limbago B, Dudeck MA, Patel J, Kallen AJ, Edwards JR, Sievert DM.** 2016. Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014. *Infect Control Hosp Epidemiol* doi:10.1017/ice.2016.174:1-14.
17. **Gentry CA, Williams RJ, 2nd.** 2015. Increased antimicrobial susceptibility rates for *Pseudomonas aeruginosa* bloodstream isolates across the Veterans Affairs Healthcare System. *Diagn Microbiol Infect Dis* **82**:215-221.
18. **Cheong HS, Kang CI, Wi YM, Ko KS, Chung DR, Lee NY, Song JH, Peck KR.** 2008. Inappropriate initial antimicrobial therapy as a risk factor for mortality in patients with community-onset *Pseudomonas aeruginosa* bacteraemia. *Eur J Clin Microbiol Infect Dis* **27**:1219-1225.
19. **Cilloniz C, Gabarrus A, Ferrer M, Puig de la Bellacasa J, Rinaudo M, Mensa J, Niederman MS, Torres A.** 2016. Community-Acquired Pneumonia Due to Multidrug- and Non-Multidrug-Resistant *Pseudomonas aeruginosa*. *Chest* **150**:415-425.
20. **Department of Veterans Affairs.** January 2014. Available at: http://www.va.gov/vhapublications/ViewPublication.asp?pub_ID=2964 (accessed May 2014). Antimicrobial Stewardship Programs (ASP) (VHA Directive 1031).

Table 1. Antibiotic Resistance Rates for *Pseudomonas aeruginosa* Respiratory and Blood Cultures among Veterans Affairs Inpatient and Outpatient Facilities by Treatment Setting from 2009 to 2013

Antibiotic Category	Setting		
	Overall	Inpatient	Outpatient
Fluoroquinolones	33 (23,938)	36 (19,634)	23 (4,304)
Carbapenems	25 (21,176)	27 (17,424)	15 (3,752)
Extended-spectrum cephalosporins	25 (24,068)	27 (19,758)	15 (4,310)
Aminoglycosides	24 (24,514)	25 (20,094)	21 (4,420)
Piperacillin/ piperacillin/tazobactam	21 (21,529)	24 (17,741)	10 (3,788)
MDR per CDC definitions	20 (24,562)	22 (20,134)	11 (4,428)
Total Number of Isolates	24,562	20,134	4,428

CDC= Centers for Disease Control and Prevention; MDR= Multidrug resistant
Data are % non-susceptible (number of isolates tested)

Extended-spectrum cephalosporins category included ceftazidime and cefepime.

Fluoroquinolones category included levofloxacin and ciprofloxacin.

Aminoglycosides category included amikacin, gentamicin, and tobramycin.

Carbapenems category included imipenem, meropenem, and doripenem.

Piperacillins included piperacillin and piperacillin/tazobactam.

CDC MDR was defined as non-susceptibility to at least one agent in at least three of the following 5 categories: aminoclycosides, carbapenems, extended-spectrum cephalosporins, fluoroquinolones, and piperacillins.

Table 2. *Pseudomonas aeruginosa* Antibiotic Resistance Rates for Respiratory and Blood Cultures among Veterans Affairs Facilities Nationally by Culture Source from 2009 to 2013

Antibiotic Category	Source		
	Overall	Lung	Blood
Fluoroquinolones	33 (23,938)	34 (20,493)	28 (3,445)
Carbapenems	25 (21,176)	25 (18,089)	20.8 (3,087)
Extended-spectrum cephalosporins	25 (24,068)	25 (20,594)	21 (3,474)
Aminoglycosides	24 (24,514)	25 (20,988)	18 (3,526)
Piperacillins	21 (21,529)	22 (18,416)	18 (3,113)
MDR per CDC definitions	20 (24,562)	21 (21,031)	17 (3,531)
Total Number of Isolates	24,562	21,031	3,531

CDC= Centers for Disease Control and Prevention; MDR= Multidrug resistant
Data are % non-susceptible (number of isolates tested)

Extended-spectrum cephalosporins category included ceftazidime and cefepime.

Fluoroquinolones category included levofloxacin and ciprofloxacin.

Aminoglycosides category included amikacin, gentamicin, and tobramycin.

Carbapenems category included imipenem, meropenem, and doripenem.

Piperacillins included piperacillin and piperacillin/tazobactam.

CDC MDR was defined as non-susceptibility to at least one agent in at least three of the following 5 categories: aminoclycosides, carbapenems, extended-spectrum cephalosporins, fluoroquinolones, and piperacillins.

**Figure 1. *Pseudomonas aeruginosa* Antibiotic Resistance Among Veterans Affairs
Inpatient Facilities by CDC Region**

AMG= Aminoglycosides; CDC= Centers for Disease Control and Prevention; E N Central= East North Central Region; E S Central= East South Central Region; ES Ceph= Extended-spectrum cephalosporin; FQ= Fluoroquinolone; MDR= Multidrug resistant; Mid Atlantic= Middle Atlantic Region; Mountain=Mountain Region; New England= New England Region; Pacific= Pacific Region; PIP= Piperacillins; S Atlantic= South Atlantic Region; W N Central= West North Central Region; W S Central= West South Central Region

Data are % non-susceptible (total number of isolates tested). Not every antibiotic category tested for every isolate tested.

Extended-spectrum cephalosporins category included ceftazidime and cefepime.
Fluoroquinolones category included levofloxacin and ciprofloxacin.
Aminoglycosides category included amikacin, gentamicin, and tobramycin.
Carbapenems category included imipenem, meropenem, and doripenem.
Piperacillins included piperacillin and piperacillin/tazobactam.
CDC MDR was defined as non-susceptibility to at least one agent in at least three of the following 5 categories: aminoclycosides, carbapenems, extended-spectrum cephalosporins, fluoroquinolones, and piperacillins.

**Figure 2. *Pseudomonas aeruginosa* Antibiotic Resistance Among Veterans Affairs
Outpatient Facilities by CDC Region**

AMG= Aminoglycosides; CDC= Centers for Disease Control and Prevention; E N Central= East North Central Region; E S Central= East South Central Region; ES Ceph= Extended-spectrum cephalosporin; FQ= Fluoroquinolone; MDR= Multidrug resistant; Mid Atlantic= Middle Atlantic Region; Mountain=Mountain Region; New England= New England Region; Pacific= Pacific Region; PIP= Piperacillins; S Atlantic= South Atlantic Region; W N Central= West North Central Region; W S Central= West South Central Region

Data are % non-susceptible (total number of isolates tested). Not every antibiotic category tested for every isolate tested.

Extended-spectrum cephalosporins category included ceftazidime and cefepime.
Fluoroquinolones category included levofloxacin and ciprofloxacin.
Aminoglycosides category included amikacin, gentamicin, and tobramycin.
Carbapenems category included imipenem, meropenem, and doripenem.
Piperacillins included piperacillin and piperacillin/tazobactam.
CDC MDR was defined as non-susceptibility to at least one agent in at least three of the following 5 categories: aminoclycosides, carbapenems, extended-spectrum cephalosporins, fluoroquinolones, and piperacillins.